Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase III Trial of Herceptin Followed by Chemotherapy Plus Herceptin Versus the Combination of Herceptin and Chemotherapy as Palliative Treatment in Patients With HER2-Overexpressing Advanced/Metastatic Breast Cancer

Trial Profile

Randomized Phase III Trial of Herceptin Followed by Chemotherapy Plus Herceptin Versus the Combination of Herceptin and Chemotherapy as Palliative Treatment in Patients With HER2-Overexpressing Advanced/Metastatic Breast Cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary) ; Paclitaxel
  • Indications Advanced breast cancer; Carcinoma; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2022 Results of safety analysis after 11 years of follow-up, presented at the 45th Annual San Antonio Breast Cancer Symposium
    • 10 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Jul 2024.
    • 19 Dec 2016 Results published in the Annals of Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top